Vantage BioTrials at SNMMI 2026
Vantage BioTrials will attend the Society of Nuclear Medicine and Molecular Imaging Annual Meeting (SNMMI 2026) from May 30 to June 2, 2026.
This global event brings together leaders in nuclear medicine, molecular imaging, and radiopharmaceutical development. It creates a space to share scientific advances and discuss real-world applications.
As innovation accelerates, clinical trial execution becomes more specialized. As a result, sponsors must rely on strong operational oversight and clear coordination.
Meet the Vantage BioTrials Team
Representing Vantage BioTrials at the meeting will be:
- Vatche Bartekian, President
- Viken Bartekian, Vice President, Corporate Development
They look forward to connecting with sponsors, investigators, and partners working in radiopharmaceutical and imaging-based development.
Radiopharmaceutical Clinical Trial Expertise
Radiopharmaceutical trials require a specialized operational approach. These studies involve complex logistics, strict regulatory expectations, and coordinated site execution.
At Vantage BioTrials, we support these programs through:
- Coordination with nuclear medicine teams and imaging sites
- Oversight of radiopharmaceutical handling and logistics
- Support for imaging endpoints and centralized review
- Risk-based monitoring tailored to complex protocols
- Collaboration with specialized clinical sites
In addition, our approach is grounded in Quality by Design (QbD). It also integrates proactive risk mitigation from the earliest stages. Therefore, teams can identify risks early and manage them throughout the trial lifecycle.
👉 Learn more about our therapeutic expertise .
What We’re Focused On at SNMMI
Today, radiopharmaceutical development continues to evolve. Consequently, clinical programs require greater coordination and operational precision.
At SNMMI, we look forward to discussing:
- Managing complexity in radiopharmaceutical trials
- Coordinating imaging infrastructure and site readiness
- Maintaining data quality and protocol compliance
- Applying structured, risk-based oversight
These priorities are directly linked to successful execution. As a result, alignment between sponsors and CRO partners remains essential.
About SNMMI
The Society of Nuclear Medicine and Molecular Imaging Annual Meeting is a leading global conference in nuclear medicine and molecular imaging.
It brings together clinicians, researchers, and industry leaders. Together, they advance innovation across diagnostics and targeted therapies.
👉 Learn more about the meeting: https://www.snmmi.org/
Connect with Vantage BioTrials
If you will be attending SNMMI 2026, we welcome the opportunity to connect.
We would be pleased to discuss how disciplined clinical trial management, proactive risk mitigation, and collaborative execution can support your radiopharmaceutical development programs.